Remote Jobs at DBV Technologies

DBV Technologies

51 - 200 employees

🧬 Biotechnology

💊 Pharmaceuticals

🔥 Funding within the last year

💰 $30M Post-IPO Secondary - DBV Technologies on 2025-10

Biotechnology • Pharmaceuticals

DBV Technologies is a global clinical-stage biopharmaceutical company developing epicutaneous immunotherapy to treat food allergies and other immune-mediated diseases. Founded by pediatricians, the company is advancing its proprietary VIASKIN® patch technology through clinical trials—including Phase 3 studies for a peanut allergy patch (DBV712) and earlier-stage programs for milk allergy (DBV135)—with the goal of re-educating the immune system using controlled skin exposure to antigens.